

Repeated vaccination with homologous influenza hemagglutinin broadens human antibody responses to unmatched flu viruses.

Yixiang Deng^{1*}, Melbourne Tang^{2*}, Ted M. Ross^{3,4}, Aaron G. Schmidt^{1,5}, Arup K. Chakraborty^{1, 2, 6-8†}, and Daniel Lingwood^{1†}

¹Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA

²Department of Physics, Massachusetts Institute of Technology, Cambridge, MA

³Center for Vaccines and Immunology, University of Georgia, Athens, GA

⁴Department of Infectious Diseases, University of Georgia, Athens, GA

⁵Department of Microbiology, Harvard Medical School, Boston, MA

⁶Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA
02139

⁷Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139

⁸Institute for Medical Engineering and Science, Massachusetts Institute of Technology,
Cambridge, MA 02139

* equal contribution

† Address correspondence to: arupc@mit.edu and dlingwood@mgh.harvard.edu

Abstract

The on-going diversification of influenza virus necessitates annual vaccine updating. The vaccine antigen, the viral spike protein hemagglutinin (HA), tends to elicit strain-specific neutralizing activity, predicting that sequential immunization with the same HA strain will boost antibodies with narrow coverage. However, repeated vaccination with homologous SARS-CoV-2 vaccine eventually elicits neutralizing activity against highly unmatched variants, questioning this immunological premise. We evaluated a longitudinal influenza vaccine cohort, where each year the subjects received the same, novel H1N1 2009 pandemic vaccine strain. Repeated vaccination gradually enhanced receptor-blocking antibodies (HAI) to highly unmatched H1N1 strains within individuals with no initial memory recall against these historical viruses. An *in silico* model of affinity maturation in germinal centers integrated with a model of differentiation and expansion of memory cells provides insight into the mechanisms underlying these results and shows how repeated exposure to the same immunogen can broaden the antibody response against diversified targets.

Introduction

Seasonal influenza vaccines are designed to elicit protective antibody responses against the viral strains predicted to dominate during an upcoming winter season (Comber et al., 2023; Fiore et al., 2009; Jordan et al., 2023; Sandor et al., 2021). The vaccine is typically trivalent or quadrivalent and aims to cover human-infecting influenza A viruses (IAV) and influenza B viruses (IBV) (Demirden et al., 2022; Reed et al., 2012; Soema et al., 2015). This has included an H1N1 vaccine strain for group 1 IAV, an H3N2 vaccine strain for group 2 IAV, and Yamagata and/or Victoria lineages for IBV. Elicitation of antibodies engaging the receptor binding site (RBS) on the influenza spike protein hemagglutinin (HA) to block viral attachment is considered a major source of protection and is routinely measured by the hemagglutination (HA) inhibition (HAI) assay (Cox, 2013; Krammer et al., 2020; Pedersen, 2014; Spackman and Sitaras, 2020). Antibody Fc effector functions also provide orthogonal immuno-protective activities (Boudreau and Alter, 2019; Boudreau et al., 2023; DiLillo et al., 2016).

A concern of seasonal influenza vaccines is the lack of universality, where vaccine coverage can be lowered by antigenic drift of the virus, or even more worrying, antigen shift leading to the emergence of pandemic flu strains (Bedi et al., 2023; Krammer et al., 2018). These limitations are also underscored by the fact that individual HA molecules tend to elicit strain-specific antibody binding or neutralizing activity (Altman et al., 2018; Angeletti and Yewdell, 2018; Bedi *et al.*, 2023; Sangesland and Lingwood, 2021). Here, sequential immunization with homologous influenza HA antigens typically serves to boost strain-limited humoral output (Henry et al., 2018; Krammer *et al.*, 2018; Krammer and Palese; Sangesland and Lingwood, 2021). Addressing these deficits has been a basis for rationally designed immune-focusing concepts tasked with re-

orienting humoral immunity upon immune subdominant sites of conservation on influenza HA (Altman *et al.*, 2018; Angeletti and Yewdell, 2018; Caradonna and Schmidt, 2021; Krammer *et al.*, 2018; Sangesland and Lingwood, 2021; Wei *et al.*, 2020). These efforts include structure-based reconfiguration and presentation of conserved HA moieties, and sequential immunization with strain variant antigens to further promote expansion of B cell memory against the invariant sites (Amitai *et al.*, 2020; Angeletti *et al.*, 2019; Boyoglu-Barnum *et al.*, 2021; Caradonna *et al.*, 2022; Nachbagauer and Palese, 2018; Sangesland *et al.*, 2019; Yassine *et al.*, 2015). A number of these ‘universal’ vaccine candidates are at various stages of clinical evaluation (Andrews *et al.*, 2023; Nachbagauer *et al.*, 2021; Widge *et al.*, 2023).

Notably however, recent human SARS-CoV-2 vaccine data warrants reconsideration of the basic premise that sequential immunization with homologous antigens elicits strong but strain-limited humoral immunity (Garcia-Beltran *et al.*, 2022; Muecksch *et al.*, 2022; Schmidt *et al.*, 2022). Three sequential vaccinations with the homologous Wuhan-strain glycoprotein spike antigen elicits neutralizing antibody responses against highly unmatched Omicron variants. Broad neutralizing activity via engagement of the SARS-CoV-2 receptor binding site was acquired after the third vaccination, consistent with a diversification of the repertoire of the antibodies elicited (Garcia-Beltran *et al.*, 2022; Muecksch *et al.*, 2022; Schmidt *et al.*, 2022). Both antigen presentation dynamics and epitope masking activities within B cell germinal centers (GCs) appear to play key roles in the emergence of this broadened antibody response (Yang *et al.*, 2023).

In the present study, we evaluated whether diversification of antibody binding/neutralization breadth via sequential immunization with homologous antigen is a general human vaccine

principle. Accordingly, we evaluated an influenza vaccine cohort of individuals sampled longitudinally over four years (2013-2016) (Boudreau *et al.*, 2023; Nunez *et al.*, 2017). HAI was measured before and after vaccination in each year, using a virus panel composed of diverse influenza A and B viruses spanning > 100 years of evolution (Nunez *et al.*, 2017). Importantly, this vaccine cohort closely followed the 2009-2010 H1N1 pandemic and included 4 years of repeat exposure to ‘non-imprinted’ /pandemic A/California/7/2009 (pHA) as the sole H1N1 vaccine strain. Annual vaccination boosted HAI to vaccine matched virus but also, to highly divergent H1N1 viruses, despite the strong lack of relatedness. Importantly this broadening did not occur via initial memory recall, but rather intensified gradually, over the four year vaccination period within individuals that were devoid of initial back-boosting against historical H1N1 viruses. To define a mechanistic framework for this effect, we extended a previous *in silico* model that accounts for B cell affinity maturation within GCs and associated memory B cell differentiation and expansion outside germinal centers (Yang *et al.*, 2023). Using this approach, we describe mechanisms that underlie the broadening of antibody coverage. We find that the broadening of the response is determined by the interplay between enhanced antigen presentation and epitope masking in germinal centers after booster shots, germline B cell affinities for different HA epitopes, and the level of conservation of these epitopes in the vaccinating strain with those on different historical variants. In these contexts, the capacity to eventually elicit broadly reactive antibody responses using a single influenza vaccine strain is discussed.

Results

The RBS Patch of the 2009 H1N1 pandemic virus is strongly divergent from prior influenza strains

We began by applying a structure based approach to define amino acid variation within the RBS (the epitope patch responsible for conferring HAI) amongst diverse IAV (H3N2 and H1N1) and IBV, spanning over 100 years of evolution (Figure 1, Table S1, Data S1). We assessed amino acid relatedness of the residues comprising the entire HA ectodomain (Figure 1A,B), and then the RBS patch, as defined by the structures of four human broadly neutralizing RBS-directed antibodies (bnAbs), each in co-complex with HA (Schmidt et al., 2015) (Figure 1C,D). The paratopes of these bnAbs structurally mimic sialic acid, the primary receptor for influenza virus (Schmidt *et al.*, 2015). In each case, the epitope footprint consists of the core viral amino acid residues responsible for binding sialyl oligosaccharide, along with a surrounding ‘ring’ of contact positions that are differentially engaged by the four bnAbs (Figure 1C). We defined the RBS patch as the sialic acid binding residues + the cumulative ‘ring’ of contact positions defined by these antibodies (Figure 1C). Amino acid relatedness values within the HA ectodomain and the RBS patch were then represented as heat maps for the influenza A and B viruses (Figure 1B,D). Within H1N1 viruses, the 2009 pandemic strain (pHA) stands out, along with A/New Jersey/1976, as strongly divergent, particularly within the RBS patch (Figure 1B,D). This is consistent with previous reports on the structure of the RBS (Cheung et al., 2020; Hong et al., 2013; Xu et al., 2010) and the fact that both 2009 pandemic virus and the 1976 outbreak in Fort Dix, New Jersey, originated from swine lineages of H1N1 (Garten et al., 2009; Gaydos et al., 2006; Mena et al., 2016; Sencer, 2011; Smith et al., 2009; Zimmer and Burke, 2009).

Sequential vaccination with homologous pHA broadly boosts HAI

To define how sequential immunization with homologous HA impacts antibody scanning breadth in humans, we evaluated the HAI coverage across the diverse viral strains from our relatedness analysis (Figure 1B,D), as elicited by repeated (4x) inoculation with influenza vaccine containing the same H1N1 component (pHA) over a four year period (2013-2016) (Nunez *et al.*, 2017) (Figure 2A). An important distinction from previous analyses of this dataset is that we now focus on the same individuals that were followed longitudinally across the four year period (n=27 individuals) (Data S1). In each year, a sample was obtained before and then twenty days after vaccination, and we first evaluated the fold change in HAI elicited against the virus panel (IBV, IAV H3N2, IAV H1N1) by each vaccine component within each year (Figure 2B,C). For H1N1, we find that pHA boosts HAI for the highly unrelated H1N1 strains, comparable to the HAI elicited for vaccine-matched A/California/07/2009; and also qualitatively similar to the HAI triggered by the H3N2 and IAB vaccine components (which are not novel pandemic hemagglutinins). These features were observed for full ectodomain or RBS patch (Figure 2B,C). Hence, immunization with homologous H1N1 pHA triggers elicitation of receptor-blocking antibodies against highly unmatched H1N1 viruses.

Sequential vaccination with homologous pHA broadens HAI with gradual kinetics in subjects that do not initially back-boost to historical strains

We next defined the kinetics of relatedness-independent broadening of H1N1 HAI over the four year period by graphing the fraction of responders vs non-responders (detectable vs non detectable boosting of HAI to each H1N1 strain) at each year (Figure 3A-C). Although pandemic HA will not be historically imprinted, memory recall of pre-existing immunity or ‘back boosting’ to historical strains would occur in response to the first antigen exposure (Akkaya *et al.*, 2020;

Henry *et al.*, 2018; Nunez *et al.*, 2017; Palm and Henry, 2019; Reusch and Angeletti, 2023; Turner *et al.*, 2020) and cannot be ruled out in the first vaccine year (2013). For this reason we focused on the initial non-responders, who boost against pHA (and the other seasonal vaccine components, see Figure 2B,C) but do not simultaneously broaden/back-boost against historical H1N1 strains after immunization in Year 1, and by definition lack B cell memory that is recalled by pHA (Figure 3A-C). The subsequent reduction of these non-responders upon sequential vaccination with pHA in later years, identifies a separate vaccine broadening effect with slower kinetics (Figure 3A-C). In this effect, the proportion of non-responders to divergent H1N1 gradually decreases during the vaccine regimen, culminating in the near absence of non-responders in Year 4. This effect is seen when the subjects are not age stratified (Figure 3A) and when the subjects are divided into older and younger ages (>50 vs <38 years) (Figure 3B,C). The corresponding increases in the proportion of responders are also observed in these groups over the vaccine regimen (Figure S1). Collectively, these data indicate that within individuals that lack initial back-boosting, sequential exposure to pHA can broaden the RBS-directed antibodies against highly unrelated H1N1.

A computational model to study the mechanistic origin of increased coverage following sequential immunization with homologous HA

To obtain mechanistic insights underlying the observed broadening of the antibody response in the absence of prior immune imprinting and back-boosting, we developed a computational model of the humoral immune response to RBS epitopes upon repeated vaccination. The model is principally an extension of our past work modeling humoral immune responses upon repeated vaccination with SARS-CoV-2 vaccine immunogens, but also builds on our other past studies

(Amitai *et al.*, 2020; Wang *et al.*, 2015; Yang *et al.*, 2023). The purpose of this model is not quantitatively fit clinical data, but to identify mechanistic principles that support the observations. Below, we outline the structure of the *in silico* model; mathematical and computational details are provided in Star Methods.

We first coarse-grained the HA RBS into three antibody epitopes (epitopes 1-3) on pHA (strain 1) and on two historical H1N1 strains (strains 2 and 3) (Figure 4A). In this model, a fraction p_i of the germline B cells target epitope i and the immunodominance hierarchy is taken to be epitope 1 > epitope 2 > epitope 3. The immunodominant epitope on pHA (epitope 1) is heavily mutated as compared to strains 2 and 3. This is because the pandemic strain would escape previously immunodominant responses that target historical strains. We further assume that epitope 2 is relatively conserved between strains 1 and 2, but not conserved between strains 1 and 3; epitope 3 is relatively conserved between strains 1 and 3, but not strains 1 and 2 (Figure 4A). In this way, we model three historical strains that are different from each other, but share some similarities as would be expected for all H1N1 viruses.

The immunodominance hierarchy of the three epitopes is reflected in the distribution of germline B cell affinities for antigen, an attribute that is important for B cell recruitment into GCs (Abbott and Crotty, 2020; Abbott *et al.*, 2018; Amitai *et al.*, 2020; Dosenovic *et al.*, 2018; Sangesland and Lingwood, 2021). Detectable germline BCR affinities for antigen can range from 10^{-7} to 10^{-4} M (Feldman *et al.*, 2021; Ronsard L, 2023; Sangesland, 2019; Sangesland *et al.*, 2022), and a dissociation constant of $\sim 10^{-6}$ M is the estimate we use for the threshold for entry into GCs (Batista and Neuberger, 1998). Since high germline affinities are rare (Feldman *et al.*, 2021; Kuraoka *et al.*, 2016; Ronsard L, 2023; Sangesland, 2019; Sangesland *et al.*, 2022), we consider the distribution of affinities to decay exponentially. More immunodominant epitopes

constitute a larger fraction p_i of germline B cells and exhibit a longer high-affinity tail (Figure 4B). We varied parameters that reflect the conservation of these epitopes and their relative immunodominance.

To then study humoral immune reactions to the different epitopes *in silico*, we modelled key steps that determine the antibody response pathway to protein antigens including: [1] antigen deposition on the surface of follicular dendritic cells (FDCs) (De Silva and Klein, 2015; Victora and Nussenzweig, 2022); [2] activation and entry of naive B cells into germinal centers (GCs), affinity and T helper-cell-driven selection within GCs (De Silva and Klein, 2015; Victora and Nussenzweig, 2022; Young and Brink, 2021), and differentiation into memory B cells and plasma cells (Akkaya *et al.*, 2020; Crotty, 2015; Palm and Henry, 2019); [3] relatively rapid expansion and differentiation of memory B cells into short-lived plasma cells during the recall responses which occur outside GCs or in extra germinal center locations (EGCs) (Moran *et al.*, 2018; Van Beek *et al.*, 2022).

A set of differential equations was used to model the dynamics of antigen deposition and presentation on FDCs (see Star Methods for details). Circulating antibodies can bind to soluble antigen to form immune complexes (ICs). For the first immunization, we assume that only weakly binding circulating IgM antibodies are available for binding to the antigen and forming ICs, which are then deposited on FDCs. ICs deposited on FDCs are longer-lived than soluble antigen. In the first few days after vaccination, soluble antigen rapidly decays (Aung *et al.*, 2023; Martin *et al.*, 2021). Therefore, the weakly binding IgM antibodies can deposit relatively small amounts of ICs on FDCs before soluble antigen decays. For subsequent immunizations, stronger binding antibodies elicited by the previous immunization are available to bind antigen and form ICs that are deposited on FDCs before soluble antigen decays. The differential equations that

describe these processes are coupled to an agent-based simulation of the stochastic processes that occur in GCs and EGCs to produce memory B cells and antibodies. The stochastic simulations also model GC entry of B cells.

In the stochastic agent-based simulations of GCs and EGCs, each B cell is an agent and the probabilities of its activation, selection, proliferation, mutation, and differentiation are calculated at each time step (0.01 days). Our model accounts for the following immunological principles and factors in the activation and selection of B cells: GC B cells internalize antigen based on their binding affinities to epitopes in the vaccine strain (Batista and Neuberger, 1998; Fleire et al., 2006); the amount of antigen internalized grows with the antigen binding free energy (or affinity) and saturates above a threshold affinity (Foote and Eisen, 1995; 2000); and individual B cells compete for subsequent T cell help to promote B cell survival. Among the B cells that are positively selected in the GC, some stochastically exit the GC and differentiate into either plasma or memory B cells (Akkaya *et al.*, 2020; Crotty, 2015; Palm and Henry, 2019). The majority of positively selected B cells are recycled for mutation-selection cycles and they proliferate and undergo somatic hypermutation (SHM) (Collins and Jackson, 2018; De Silva and Klein, 2015; Glanville et al., 2009; Li et al., 2004; Mesin et al., 2016; Victora and Nussenzweig, 2012; 2022). SHM is responsible for affinity-changing mutations, though it also leads to apoptosis or no affinity change with different probabilities (Amitai *et al.*, 2020; Wang *et al.*, 2015; Yang *et al.*, 2023; Zhang and Shakhnovich, 2010). Based on data from experiments on affinity changes upon mutations at protein-protein interfaces, the change in affinity due to mutation is drawn from a log normal distribution with only 5 % of mutations being beneficial (Kumar and Gromiha, 2006; Zhang and Shakhnovich, 2010). A summary of the mathematical details of the steps described above is provided in Star Methods.

In our model, memory cells are stochastically selected in an affinity-dependent way and expanded in EGCs via the same processes as in GCs, except that there are few to no mutations (none in our model) (Moran *et al.*, 2018; Van Beek *et al.*, 2022; Yang *et al.*, 2023). B cells exiting EGCs differentiate into antibody-secreting plasma cells with a probability of 0.6, because experimental data shows that 60 % of new proliferating memory B cells differentiate into plasma cells (Moran *et al.*, 2018). These plasma cells produce antibodies at rates estimated from experiments (Goel *et al.*, 2021; Muecksch *et al.*, 2022). Our model also incorporates epitope masking in which circulating antibodies specific for a given epitope can enter ongoing GCs and EGCs and compete with B cells specific for the same epitope (Bergstrom *et al.*, 2017; Schaefer-Babajew *et al.*, 2023; Tas *et al.*, 2022; Zarnitsyna *et al.*, 2016).

While GC and EGC processes are driven by the vaccine antigen (strain 1), we also track the affinities of the resulting memory B cells and antibodies for strains 2 and 3 as well. A B cell's affinity for each strain depends on its initial affinity and the affinity-changing mutations that occur within the GC. The size of affinity-changes upon mutation for the three epitopes on different strains are drawn from correlated log-normal distributions. The level of correlation is described by a parameter, ρ , that determines a covariance matrix. This parameter is related to the level of conservation and amino acid relatedness between the strains for the B cell's target epitope. For instance, if 70% of the amino acids in an epitope are shared between strains 1 and 2, we can approximate that ~70% of the beneficial mutations for B cells targeting this epitope in strain 1 are beneficial for strain 2 as well. The value of ρ for B cells targeting epitope 2 is high between strains 1 and 2, but low between strains 1 and 3. The value of ρ for B cells targeting epitope 3 is high between strains 1 and 3, but low between strains 1 and 2. The value of ρ for B cells targeting epitope 1 is low between strain 1 and strains 2 and 3 as it is poorly conserved in

historical strains. We vary the values of the parameter, ρ , and study the effects.

For every immunization, we simulate 200 GCs and 1 EGC. Ten different simulations are carried out for any given condition and the results shown are averages over these simulations. The parameters used in the simulations are provided in Table S2.

Booster shots of homologous pHA provide increasing coverage of historical strains through pathways that characterize the humoral response

Figure 5A shows the results of our simulations for antibody titers elicited against strain 1 (pHA) and the two historical strains (strains 2 and 3) after each of four immunizations with strain 1. The titers are calculated based on the affinity and number of antibodies that target the epitopes in each strain. After the first immunization, significant titers of antibodies are generated only against the dominant epitope of strain 1. However, after the second immunization the titers are boosted against all strains, including strains 2 and 3. Continued boosting with pHA continues to amplify heterologous coverage, even when the homologous boosting titer has plateaued.

Experiments show that injected soluble antigen decays relatively rapidly (Aung *et al.*, 2023; Martin *et al.*, 2021; Tam *et al.*, 2016). The vaccine antigen is the pandemic strain and the individuals studied do not initially backboost responses to historical strains. Therefore, upon the first immunization only generic circulating IgM antibodies, with low affinity for the antigen, are available to form the immune complexes needed for antigen deposition on FDCs (see computational methods section). Thus, our computational results show that very little antigen is deposited on FDCs after the first immunization with a new antigen (Figure 5B).

The germline B cells targeting the immunodominant epitope on strain 1 are more abundant and generally have higher affinities than the B cells engaging the subdominant epitopes. When antigen available on FDCs is low after the first immunization, the greater abundance and

affinities of these germline B cells confers an especially strong advantage to them in entering GCs compared to B cells targeting subdominant epitopes. Furthermore, they also are much more likely to dominate GC reactions during affinity maturation. Thus, the high affinity memory B cells generated after the first immunization predominantly target the immunodominant epitope (Figure 5C, top panel).

After the second immunization, the EGCs facilitate the production of antibodies that engage strain 1, but not the historical strains. This is because the available memory B cells after the first immunization largely target the immunodominant epitope that is not conserved in the historical strains (Figure 5C, top panel). Thus, for many days after the second immunization, significant titers of antibodies that can target historical strains are not elicited (Figure 5A). However, secondary GCs also form during this time. Upon the second immunization, higher affinity IgG antibodies specific for the antigen that were generated during the first immunization are available to bind to the antigen and deposit it on FDCs before the antigen is degraded (Figure 5B). Higher amounts of deposited antigen allow lower-affinity germline B cells that target subdominant epitopes to enter the GC and be positively selected. As affinity maturation proceeds, these GC B cells acquire higher affinity to the subdominant epitopes that are relatively conserved between strain 1 and the historical strains, and generate high affinity memory B cells (Figure 5C middle panel). The plasma cells produced by the GCs produce antibodies that engage strains 2 and 3 (particularly strain 2 since epitope 2, the second most dominant epitope, is relatively conserved between strains 1 and 2).

After the third immunization, memory cells generated after the second immunization that target epitopes 2 and 3 with high affinity are also selected based on their affinities and expanded in the EGC. This results in further amplification of antibodies that target epitopes 2 and 3 (Figure

5A). Antigen deposition on FDCs is also somewhat elevated after the third immunization (Figure 5B). So, strain 3 is engaged more potently and this increases the relative number of memory B cells targeting epitope 3 compared to epitope 2 among the memory B cells generated in GCs after the third immunization (Figure 5C, bottom panel). As a consequence, the difference between the titers produced against epitopes 2 and 3 is further decreased after the fourth immunization (Figure 5A). However, the overall improvements to antibody titers are minor because antigen presentation in the GCs and expansion of memory B cells in EGCs is similar to that after the third immunization.

The relative coverage of strains 2 and 3 upon repeated vaccination depends upon the relative immunodominance of epitopes 2 and 3 in the pool of germline B cells. To test the effects of modifying the immunodominance hierarchy, we increased the fraction of germline B cells that target epitope 2, and decreased the fraction that target epitope 3. This enhances the immunodominance of epitope 2 over epitope 3. Consequently, as shown in Figure 5D, the responses to epitope 3 and to historical strain 3 in which epitope 3 is conserved are less potent compared to the results shown in Figure 5A.

The relative coverage of historical strains also depends on the conservation of subdominant epitopes between the historical and immunizing strains. In Figure 5A, the conservation of epitope 2 between strains 1 and 2 and of epitope 3 between strains 1 and 3 are the same. The results show that higher titers are elicited against strain 2 than strain 3, which aligns with the immunodominance of epitope 2 over epitope 3. However, it is possible that a more immunodominant epitope is less conserved as viruses mutate to avoid immune detection (Altman *et al.*, 2018; Angeletti *et al.*, 2017; Angeletti and Yewdell, 2018). Thus, we examined the effects of reducing the conservation of epitope 2 while fixing the conservation of epitope 3. If

the conservation of epitope 2 between strains 1 and 2 is decreased below a critical value (see Figure S2), the advantage of epitope 2 due to a more favorable germline distribution is outweighed by weaker conservation. In Figure 5E, epitope 2 is more weakly conserved than in Figure 5A (but the germline immunodominance hierarchy is kept the same), resulting in lower titers against strain 2 than against strain 3.

Epitope masking enhances the generation of antibodies that can engage historical variants upon boosting with unmatched homologous HA

Circulating antibodies can enter GCs and bind to their corresponding epitopes on antigen presented on FDCs (Schaefer-Babajew *et al.*, 2023; Tas *et al.*, 2022). This masking of an epitope by soluble antibodies lowers the effective amount of antigen available to GC B cells targeting the same epitope, reducing their competitive fitness within the GC. This property of epitope masking by circulating antibodies can be applied to regulate the GC participation of naive B cells according to epitope specificity and the competitive environment for GC B cells (Schaefer-Babajew *et al.*, 2023; Tas *et al.*, 2022; Yang *et al.*, 2023). Our computational model shows that after the second immunization, most of the circulating antibodies bind to the dominant epitope. This is because most of the memory B cells produced after the first immunization are directed against the dominant epitope (Figure 5C and 6C), and these memory cells are rapidly expanded in EGCs after the second immunization to generate the corresponding antibodies. Accordingly, we find that the entry and selection of subdominant-targeting B cells during affinity maturation are enhanced by including the effects of epitope masking which generates more memory cells that target the subdominant epitopes (Figure 6C and 6D). This results in larger antibody titers targeting strains 2 and 3 if epitope masking is included (Figure 6A). Likewise, after the third immunization, the antibodies from the second vaccination begin to mask epitope 2, promoting

the generation of memory B cells and antibodies targeting epitope 3 (Figure 6). This feature of increasing antibody titers against the historical strains is observed when we consider two cases of epitope masking (Figure 6A and 6B): [1] where the three epitopes under consideration are non-overlapping; and [2] where the epitopes overlap with each other. The first case shows the largest effect of epitope masking. In the second case, epitope masking effects remain significant, even if we consider a modest level of epitope overlap (e.g. 30% between epitope 1 (dominant) and epitope 2 (subdominant); and 30% between epitope 1 (dominant) and epitope 3 (subdominant)).

Epitope overlap between dominant and subdominant epitopes generally decreases titers against historical strains compared to fully distinct epitopes. However, after the third vaccination the antibody response titer against strain 2 is higher when there is epitope overlap (Figure 6B, right panel). This is because the second immunization produces more memory cells targeting the dominant epitope when there is epitope overlap (Figure 6D). These memory cells are rapidly expanded in EGCs and so antibodies mask the dominant epitope more strongly during the third immunization when the epitopes overlap. This leads to the production of more high-affinity B cells that target epitope 2 after the third immunization, and subsequently higher titers against strain 2.

Discussion

Our results reveal broadening of antibody coverage following repeated immunization with homologous pHA. This occurred over a period when the subjects had limited imprinting to this vaccine strain, and the process occurred gradually within individuals that did not initially ‘back-boost’ against historical H1N1 strains. These findings are consistent with sequential exposure to SARS-CoV-2 mRNA vaccines, where repeated immunization with the homologous Wuhan

vaccine strain eventually elicits non-imprinted coverage against highly unmatched Omicron-lineages of SARS-CoV-2 (Garcia-Beltran *et al.*, 2022; Muecksch *et al.*, 2022; Schmidt *et al.*, 2022). Our computational results describe how aspects of the humoral response (enhanced antigen presentation on FDCs and epitope masking) are a likely origin of eliciting non-imprinted antibody breadth to influenza HA. These mechanisms are consistent with the immune reactions that broaden antibodies after boosting with the homologous SARS-CoV-2 vaccine (Yang *et al.*, 2023). Collectively, our results point to a general feature of the humoral response that intrinsically broadens antibodies against unmatched/diversified antigen targets upon repeated vaccination with the same novel antigen.

This principle of preserving diversified or ‘non-homogenized’ antibody output during ongoing immune reactions has emerged as an important theme for germinal center and memory B cell responses to protein antigens (de Carvalho *et al.*, 2023; Hagglof *et al.*, 2023; Kuraoka *et al.*, 2016; Mesin *et al.*, 2016; Mesin *et al.*, 2020; Radmacher *et al.*, 1998; Ronsard L, 2023; Sabouri *et al.*, 2014; Silver *et al.*, 2018; Tas *et al.*, 2016; Van Beek *et al.*, 2022). Our *in silico* results would suggest that intrinsic broadening of the antibodies generated in response to homologous antigen is an extension of this fundamental principle, enabling polyspecific responses and broad B cell reactivities that are tuned by antigen presentation and epitope masking effects.

Operationally, it will be important to integrate this information to define the number of homologous immunizations needed to elicit a given level of vaccine coverage of historical or new strains. Our simulations indicate antibody broadening depends on the interplay of several key factors including: the precursor frequencies of germline B cells targeting these epitopes, the affinities of germline B cells for their target epitopes, and the conservation of shared epitopes within the RBS. Precursor frequencies and germline affinities determine the B cell pool’s initial

affinities toward target strains—historical or emergent—while conservation of shared epitopes governs how those affinities change during affinity maturation in response to selection of GC B cells for their affinities to the immunizing strain. Simulation results show that the effects of the precursor frequencies and germline affinities can compete with the effects of epitope conservation in determining the coverage of a particular strain.

Our results also suggest that the germline B cell-mediated effects noted above are particularly important in earlier stages of the sequential vaccine regimen. But once higher affinity antibodies circulate (and recall of B cell memory becomes operational), epitope masking effects and enhanced antigen deposition on FDCs further modulate the immunodominance hierarchy to favor responses to sub-dominant epitopes. While our model does not account for memory B cells seeding secondary GCs, our previous work indicates that if more memory B cells enter secondary GCs the evolution of broadened antibody responses is diluted (Yang *et al.*, 2023).

In all cases, our simulations recapitulate the clinical vaccine results in a qualitative manner. This owes to our development of a simplified model for the vaccine antigen, its relation to historical strains, and the characteristics of the germline B cells that engage RBS epitopes. While recapitulation of antibody broadening through simplified computational models points to fundamental/core features of adaptive immunity, more comprehensive epitope mapping of the B cell responses to the RBS targets (structure, engagement affinity, immunodominance patterns) will be needed to assemble more complete prediction maps to guide vaccine design.

In summary, we describe a phenomenon that defies the long-held view that sequential immunization with homologous influenza HA antigens serves to only/principally reinforce the boosting of antibodies with narrow coverage (Henry *et al.*, 2018; Krammer *et al.*, 2018;

Krammer and Palese; Sangesland and Lingwood, 2021). Previous B cell epitope prediction algorithms have failed to computationally delineate and accurately predict patterns in the humoral response (Mahanty et al., 2015; Rockberg and Uhlen, 2009; Sela-Culang et al., 2013; Van Regenmortel, 2002; 2011), but by modeling the key immunological steps that underscore adaptive immune reactions to protein antigen (Akkaya *et al.*, 2020; Crotty, 2015; De Silva and Klein, 2015; Palm and Henry, 2019; Victora and Nussenzweig, 2022; Young and Brink, 2021), we recapitulate the clinical findings and describe mechanisms that underlie them. This broadening effect has thus far only been observed in human antibody responses to vaccination and we suggest that it may further inform universal vaccine approaches (Caradonna and Schmidt, 2021; Krammer *et al.*, 2018; Sangesland and Lingwood, 2021; Wei *et al.*, 2020). Immunologically, we suggest that antibody broadening reflects an in-built feature of continued B cell diversification, a principle that will insure antibody complementarity to hypervariable antigen targets.

Limits of the Study

This work lays the groundwork to experimentally define factors identified as significant for antibody broadening *in vivo*, including epitope conservation, epitope masking, and antigen presentation on FDCs. While the model predicts that epitope conservation impacts titers against historical strains, the data examined in this study do not show a clear trend between amino acid similarity with the vaccine strain and the titer levels or coverage kinetics among H1N1 strains. Exploring alternate experimental metrics for epitope conservation instead of amino acid similarity, along with examination of diverse sets of clinical data, can improve the model and lead to better congruence between model predictions and data. In addition, experimentally

defining the relative contribution of epitope masking and antigen presentation on FDCs will necessitate vaccine/immune challenge models where these parameters can be measured individually and that accurately reflect human humoral response features (Aung *et al.*, 2023; Schaefer-Babajew *et al.*, 2023; Tas *et al.*, 2022; Zarnitsyna *et al.*, 2016). In humans, an accurate description of individual imprinted B cell memory to influenza HA will also be needed to predict the broadening activity of homologous influenza vaccine regimen, in lieu of another pandemic influenza virus strain that does not back-boost to historical strains.

Acknowledgements

MT and AKC acknowledge significant discussions with L. Yang. DL and YD thank the Lingwood lab for helpful feedback. The authors acknowledge support from NIH grants [U19AI057229 (AKC); AI155447, AI137057, and AI153098 (DL) AI146779, AI089618 (AGS)]; NIH contract 75N93019C00050 (AGS); NIH contract 75N93019C00052 (D.L.); as well as support the Ragon Institute of MGH, MIT & Harvard. YD was supported by a Schwartz AI initiative. TMR is also supported, in part, as a Georgia Research Alliance Eminent Scholar. The authors would also like to acknowledge Harvard CFAR for ongoing support through P30 AI060354.

Author contributions

Conceptualization, DL, AKC; Investigation, YD, MT; Writing – Original Draft, YD, MT, AKC, DL.; Writing – Review and Editing, all authors; Funding Acquisition, DL, AKC; Supervision, DL, AKC.

Declaration of interests

DL reports SAB membership for Metaphore Bio (a Flagship company), Tendel Therapies, and Lattice Therapeutics Inc. AKC is a consultant (titled “Academic Partner”) of Flagship Pioneering, a consultant and member of the Strategic Oversight Board of Apriori Bio (a Flagship company), and a consultant and SAB member of Metaphore Bio.

STAR METHODS

LEAD CONTACT AND MATERIALS AVAILABILITY

Lead Contact

Further information and requests for reagents should be directed to and will be fulfilled by Daniel Lingwood (dlingwood@mgh.harvard.edu) and Arup Chakraborty (arupc@mit.edu).

Materials Availability

There are no restrictions on the availability on the materials used in this study.

Data and Code Availability

All longitudinal HAI values used in this study are provided in Data S1. All original code and data files for the computational results have been deposited at <https://github.com/mtang17/flu> and are publicly available.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

We evaluated the HAI titers elicited by a clinical influenza vaccine that was sequentially immunized (4x) over a four year period (2013-2016) and contained the same H1 component (A/California/7/2009) in each of the vaccine years (Nunez *et al.*, 2017). An important distinction from the previous analysis is that we focused only on individuals that were longitudinally sampled across the four year period (n=27 individuals; subjects are grouped into two age categories: above 50 years old and below 38 years old, see Data S1). In each year a blood sample was obtained before and then twenty days after vaccination. HAI titers for viruses spanning 100 years of influenza evolution were measured in each of these samples (Nunez *et al.*, 2017) (see Data S1 and Table S1). The H1N1 viral panel for HAI comprised: *A/South Carolina/1/1918*, *A/Weiss/JY2/1943*, *A/Fort Monmouth/1/1947*, *A/Denver/1/1957*, *A/New Jersey/6/1976*, *A/USSR/90/1977*, *A/Chile/1/1983*, *A/Singapore/6/1986*, *A/Texas/36/1991*, *A/Beijing/262/1995*, *A/New Caledonia/20/1999*, *A/Solomon Island/3/2006*, *A/Brisbane/59/2007*, *A/California/07/2009*. The H3N2 vaccine panel for HAI comprised: *A/Hong/Kong/1/1968*, *A/Hong/Kong/4801/2014*, *A/Nanchang/933/1995*, *A/New/York/55/2004*, *A/Panama/2007/1999*, *A/Perth/16/2009*, *A/Port/Chalmers/12/1973*, *A/Shandong/9/1993*, *A/Switzerland/9715293/2013*, *A/Sydney/5/1997*, *A/Texas/1/1977*, *A/Texas/50/2012*, *A/Victoria/361/2011*, *A/Wisconsin/67/2005*. The IBV viral panel for HAI included: *B/Brisbane/60/2008*, *B/Florida/4/2006*, *B/Harbin/7/1994*, *B/Hong/Kong/330/2001*, *B/Lee/1940*, *B/Malaysia/2506/2004*, *B/Massachusetts/2/2012*, *B/Phuket/3073/2013*, *B/Texas/06/2011*, *B/Wisconsin/1/2010*, *B/Yamagata/16/1988*

METHOD DETAILS

Amino acid relatedness in HA ectodomains or within the RBS patch

Amino acid sequences of HA ectodomains from the different strains used in HAI were obtained from Genbank (<https://www.ncbi.nlm.nih.gov/genbank/>) or GISAID (<https://gisaid.org/>) (Table S1). The amino acid positions comprising the HA RBS patch was defined by the structures of four human broadly neutralizing RBS-directed antibodies, each in co-complex with HA (Schmidt *et al.*, 2015). We used this information to define amino acid relatedness between the HA glycoproteins of all the influenza viruses used in our HAI panel. Pairwise relatedness was defined for both full length HA ectodomain and for the RBS patch. In both cases, amino acid sequence relatedness was obtained by first aligning two amino acid sequences and then computing the ratio of matched amino acid counts over the total amino acid counts in the aligned sequences. Heatmaps visualizing the pairwise amino acid sequence relatedness values were graphed using “pheatmap” function from R package “pheatmap” (version 1.0.12). Amino acid relatedness is represented as epitope conservation with the parameter ρ in the computational model (see modeling section below).

Analysis of HAI titers in relation to amino acid relatedness

We constructed dot plots to visualize the relationship between the fold change of HAI titers to the individual viruses in relation to their amino acid relatedness (for both the HA ectodomain and RBS patch) to the vaccine strain used in each year. In the case of the H1 vaccine component, the same H1 vaccine strain (A/California/7/2009) was used in each year. These plots were generated using

the “geom_point” function from R package “ggplot2” (version 3.4.2). The fold change of HAI titer for each patient was computed by dividing the post-vaccination HAI titer by the corresponding pre-vaccination HAI titer.

Longitudinal analysis of antibody broadening

To evaluate antibody broadening in response to homologous H1 (A/California/7/2009) we divided the HAI titers for H1N1 viruses from each individual subject into responders and non-responders to each viral strain in each year. Responders were defined by having non-decreasing fold changes of HAI titers (post-vaccination HAI titer / pre-vaccination HAI titer), i.e. fold change of HAI titers greater than 1. The non-responders were defined by having decreasing fold changes of HAI titers (post-vaccination HAI titer / pre-vaccination HAI titer), i.e. fold change of HAI titers less than 1. We tracked patients in the two age groups: >50 years old, having four years of complete HAI titers (2013-2016); and <38 years old, having three years of complete HAI titers (2014-2016). Bar plots showing the responder and non-responder ratios was graphed using “geom_bar” function from R package “ggplot2” (version 3.4.2). Linear regression analyses were also performed on the fraction of responders (or non-responders) in each year after standardizing the responder (or non-responder) value to the number of subjects in each age group (>50 years old or <38 years old). The linear regressions were performed using “ggscatter” function with the fitting equation shown by “stat_regline_equation” function from R package “ggpubr” (version 0.6.0). Corresponding P and r^2 values were computed using “lm” function from R package “stats” (version 4.3.1).

Immune Reactions in silico

The computational model is adapted from past work on the effects of repeated vaccination with COVID vaccines (Yang *et al.*, 2023). Changes to the original model are described in the main text and below, along with key mathematical equations that describe the model. Interested readers can find in-depth rationale for model development, exploration of alternative model structures, and further analysis of parameter sensitivity in the earlier paper on the outcome of multiple immunizations with COVID vaccines (Yang *et al.*, 2023). We use the same symbols to denote quantities as in the paper on COVID vaccines (Yang *et al.*, 2023).

Differential equations describe antigen dynamics and this is combined with stochastic simulations of GC and EGC processes. The time step is 0.01 day. For each situation, 200 GCs are simulated, and from the second immunization on, 1 EGC is simulated along with the GCs. Ten such simulations are carried out for each set of conditions and the results are averaged over the ten simulations to report results.

Antigen dynamics

Differential equations describe the reactions that govern the concentration of antigen and antibody, as shown in the table below. We use the following abbreviations and symbols: soluble antigen (Ag), soluble antibody (Ig), soluble immune complex (IC), immune complex on follicular dendritic cell (IC-FDC), plasma cell (PC), rate of decay (d), rate of reaction (k), dissociation constant of serum antibodies (K_d), dissociation constant of plasma cell BCRs (K_d^{PC}).

Equation	Reaction(s)	Description
----------	-------------	-------------

$\frac{[Ag][Ig]}{[IC]} = K_d$	$Ag + Ig \leftrightarrow IC$	Fast equilibrium for formation of immune complex
$\partial_t[Ag] = -d_{Ag}[Ag]$	$Ag \rightarrow \emptyset$	Decay of free soluble antigen
$\partial_t[IC] = -k_{deposit}[IC]$ $\partial_t[IC - FDC] = k_{deposit}[IC]$ $- d_{IC}[IC - FDC]$	$IC \rightarrow IC - FDC$ $IC - FDC \rightarrow \emptyset$	Immune complex transport to follicular dendritic cells Consumption and decay of antigen on follicular dendritic cells
$\partial_t[Ig] = k_{Ig}[PC] - d_{Ig}[Ig]$	$PC \rightarrow PC + Ig$ $Ig \rightarrow \emptyset$	Antibody production by plasma cells Decay of free soluble antigen
$\partial_t K_a = \frac{(K_a^{PC} - K_a)k_{Ig}[PC]}{[Ig] + [IC]}$	-	Derived from equations above, as detailed in supplement of Yang, et al. (2023).

The parameters used in these equations can be found in Table S2, and are identical to our previous publication (Yang *et al.*, 2023). Upon the first vaccination, only weakly binding IgM antibodies are available for binding to soluble antigen and depositing ICs on to FDCs. After subsequent vaccinations, antigen specific antibodies are available.

B cell dynamics in GCs and EGCs

Each GC is associated with a pool of 2000 naïve B cells (Yang *et al.*, 2023). A fraction p_i of these naïve B cells target epitope i . We model 3 epitopes of the influenza spike protein, which is an increase from the 2 epitopes previously used to model the SARS-CoV-2 spike protein (Yang

et al., 2023). This allows us to account for the diversity in influenza strains, each with distinct epitopes that may be conserved with the H1N1 CA09 vaccine strain (see main text).

The germline binding affinities $E = -\log(K_d)$ of the naïve B cells for the vaccine strain have discrete values between 6 and 8, expressed as $E_k = 6 + 0.2k$ for $k = 0, 1, \dots, 10$. The lower value of 6 was chosen based on data as described in main text, and germline affinities that are one hundred times greater have also been observed (Yang *et al.*, 2023). The frequency of naïve B cells targeting epitope i in the affinity bin E_k is a truncated geometric distribution and is determined as follows:

$$f_i(E_k) = N_{naive} p_i \frac{e^{-r_i(E_k - E_0)}}{\sum_k e^{-r_i(E_k - E_0)}}$$

where the number of naïve B cells N_{naive} is 2000 and the minimum germline affinity E_0 is 6 in these simulations. r_i is determined such that

$$f_i(E_i^*) = p_i$$

where E_i^* is defined as follows using the parameters E_1^h , dE_{12} , and dE_{13} :

$$E_1^* = E_1^h$$

$$E_2^* = E_1^h - dE_{12}$$

$$E_3^* = E_1^h - dE_{13}$$

The parameters are set such that $E_1^* > E_2^* > E_3^*$, reflecting the generally higher affinities for more dominant epitopes. The immunodominance hierarchy is further enforced by setting $p_1 > p_2 > p_3$, meaning that more dominant epitopes are targeted by a greater number of naïve B cells.

Since individuals initially have a weak response (sub-dominant) against historical influenza strains, the germline binding affinity of all naïve B cells that target the epitopes that are conserved between the vaccinating strain and historical strains is set to the lowest possible germline affinity in these simulations ($E = 6$).

After initializing the pool of naïve B cells, the B cells can be stochastically activated. The probability of activation for a naïve B cell depends on the quantity of vaccine antigen it captures, which is determined by both the antigen concentration and binding affinity to the vaccine strain.

The amount of antigen captured by B cell j is modeled as

$$A_j = \left(\frac{C}{C_0} 10^{\min(E_j, 10) - E_0} \right)^K$$

where C is the effective antigen concentration, C_0 is the reference antigen concentration, E_j is the B cell's binding affinity for vaccine strain, and E_0 is the reference affinity. The effective antigen concentration is $C = 0.01([Ag] + [IC]) + [IC - FDC]$, where antigens presented on FDCs are more potent at activating B cells (Kim et al., 2006). The selection stringency K represents how sensitive the amount of antigen captured is to small differences in antigen concentration or binding affinity. The probability of activation is $P(\text{B cell } j \text{ is activated}) = \min(A_j, 1)$.

Activated B cells can then stochastically enter the GC. Entry into the GC depends on antigen captured and competition for limited T cell help (Lee et al., 2021; Schwickert et al., 2011). The rate of entry for an activated B cell j is

$$\lambda_j = \frac{\frac{N_{max}}{N_{activated}} \frac{A_j}{\langle A \rangle}}{1 + \frac{N_{max}}{N_{activated}} \frac{A_j}{\langle A \rangle}}$$

where $N_{activated}$ is the number of activated B cells, N_{max} is the capacity for GC entry based on limited T cell help, and $\langle A \rangle$ is the average amount of antigen captured by all B cells. Thus, $\frac{N_{max}}{N_{activated}}$ represents the competition between B cells for T cell help and $\frac{A_j}{\langle A \rangle}$ represents the competitive advantage of a particular B cell j over other cells. The probability of GC entry is $P(B \text{ cell } j \text{ enters GC}) = 1 - e^{-\lambda_j dt}$.

GC B cells also capture antigen and compete for T cell help to become stochastically activated. The rate of positive selection is

$$\beta_j = \beta_{max} \frac{\frac{N_T}{N_{activated}} \frac{A_j}{\langle A \rangle}}{1 + \frac{N_T}{N_{activated}} \frac{A_j}{\langle A \rangle}}$$

where β_{max} is the maximum rate of positive selection, $N_{activated}$ is the number of activated B cells, and N_T is the number of helper T cells.

If a B cell is positively selected, it exits the GC with probability p_{exit} or is recycled for mutation-selection cycles in the GC with probability $1 - p_{exit}$. If the B cell exits, it becomes a plasma cell with probability p_{plasma} or a memory cell with probability $1 - p_{plasma}$. If the B cell proliferates, one of the daughter cells mutates. The mutation may change affinity (probability 0.2), result in apoptosis (probability 0.3), or be silent (Zhang and Shakhnovich, 2010).

Each B cell has a string of 0s and 1s for the residues on the paratope with a total length of n_{res} . The string of residues starts as all 0s in a naïve B cell. When there is an affinity-changing mutation, one of the bits (residues) is randomly chosen and flipped. The change in affinity is

drawn from a shifted log-normal distribution, independently for each residue (Kumar and Gromiha, 2006; Zhang and Shakhnovich, 2010). The affinity of a B cell j for a particular strain is determined by both the germline affinity and affinity-changing mutations, as follows:

$$E_j^{strain} = E_j^{0,strain} + \sum_{k=0}^{n_{res}} \delta_{j,k} s_{j,k}^{strain}$$

where $E_j^{0,strain}$ is the germline affinity, $\delta_{j,k} \in \{0,1\}$ is the mutational state of residue k , and $s_{j,k}^{strain}$ is the change in affinity due to a mutation at residue k . $s_{j,k}^{strain}$ is correlated between different strains, as follows ($s_{j,k}^1$ is the change in affinity for strain 1, $s_{j,k}^2$ is the change in affinity for strain 2, and so on). The values of $s_{j,k}^{strain}$ are drawn from identical log normal distributions that are correlated as follows:

$$[s_{j,k}^1, s_{j,k}^2, s_{j,k}^3] \sim e^{N(\mu, \sigma^2 \Sigma)} - \epsilon$$

$$\Sigma = \begin{bmatrix} 1 & \rho_{12} & \rho_{13} \\ \rho_{12} & 1 & 0 \\ \rho_{13} & 0 & 1 \end{bmatrix}$$

where μ, σ, ϵ were chosen such that only ~5 % of affinity-changing mutations are beneficial, as shown in experimental studies (Kumar and Gromiha, 2006; Zhang and Shakhnovich, 2010). Σ is the correlation matrix and ρ_{12} and ρ_{13} parameterize the correlation of affinity changes between strains 1 and 2 and strains 1 and 3, respectively. The level of correlation is related to the level of conservation between the strains for B cell j 's target epitope, as described in the main text. We only consider correlation between the vaccine strain (strain 1) and historical strains (strains 2 and 3), but not between strains 2 and 3. Since B cells are selected for their affinity to strain 1, the correlation between strains 2 and 3 does not impact the nature of the antibody or memory B cell response.

In this study, we considered the correlation between three strains compared to two strains in our COVID model (Yang *et al.*, 2023) since we examined the effect of sequential immunization on B cell responses against multiple unmatched influenza strains.

After the first immunization, pre-existing memory cells stochastically expand and differentiate in the EGC. The memory cells are selected for expansion in the same affinity-dependent way as GC B cells, except memory cells do not undergo mutation in our model. The number of helper T cells is set to its maximum value to reflect the faster kinetics of the EGC (Goel *et al.*, 2021; Moran *et al.*, 2019). B cells exiting the EGC differentiate into plasma cells with a probability of 0.6 (Moran *et al.*, 2018).

Epitope masking

When epitope masking is considered, GC B cells specific for a particular epitope cannot capture antigen on FDCs if that epitope is bound to circulating antibodies. These circulating antibodies are produced by plasma cells from previous immunizations and expansion and differentiation of memory cells from previous immunizations. The amount of bound antigen is calculated using fast equilibrium of receptor-ligand binding:

$$[Ag_{masked}]^2 - ([Ag] + [Ig]^* + K_d^*)[Ag_{masked}] + [Ag][Ig]^* = 0$$

where $[Ag_{masked}]$ is the concentration of masked, i.e. bound, antigen, $[Ig]^*$ is the effective antibody concentration, and K_d^* is the effective average dissociation constant. The values in the equation above are calculated separately for each epitope. When we do not consider epitope overlap, $[Ig]^*$ and K_d^* are exactly the concentration of antibodies targeting a particular epitope

and the average dissociation constant of those antibodies. In the presence of epitope overlap, some antibodies can mask epitopes that spatially overlap with their primary target. In this case

$$\begin{bmatrix} [Ig_1]^* \\ [Ig_2]^* \\ [Ig_3]^* \end{bmatrix} = \begin{bmatrix} 1 & q_{12} & q_{13} \\ q_{12} & 1 & q_{23} \\ q_{13} & q_{23} & 1 \end{bmatrix} \begin{bmatrix} [Ig_1] \\ [Ig_2] \\ [Ig_3] \end{bmatrix}$$

where $[Ig_i]^*$ is the effective concentration of antibodies targeting epitope i and $[Ig_i]$ is the actual concentration of antibodies targeting epitope i . q_{mn} describes the overlap between epitope m and n and is the fraction of antibodies targeting epitope m that can mask epitope n (and vice versa).

The effective average dissociation constant $K_{d,i}^*$ is calculated similarly:

$$\begin{bmatrix} [Ig_1]^*/K_{d,1}^* \\ [Ig_2]^*/K_{d,2}^* \\ [Ig_3]^*/K_{d,3}^* \end{bmatrix} = \begin{bmatrix} 1 & q_{12} & q_{13} \\ q_{12} & 1 & q_{23} \\ q_{13} & q_{23} & 1 \end{bmatrix} \begin{bmatrix} [Ig_1]/K_{d,1} \\ [Ig_2]/K_{d,2} \\ [Ig_3]/K_{d,3} \end{bmatrix}.$$

The concentration of bound antigen $[Ag_{masked}]$ is then calculated and subtracted from the total antigen concentration since bound antigen cannot be seen by B cells. The resulting antigen concentration is then scaled such that the fraction of soluble antigen and fraction of antigen on the FDC match those fractions before epitope masking is not considered.

Modifications to the original model

As a summary, the revised model includes three epitopes instead of two epitopes and considers three strains instead of two. This manifests in the distribution of naïve B cells' germline affinities, the effective antigen concentration in epitope masking, and the correlated affinity changes in the GC. Using multiple epitopes and strains accounts for the diversity in influenza strains, each with distinct epitopes that may be conserved with the vaccine strain. By examining the relationships between multiple epitopes and strains, we gained general insights into factors that affect the

number of immunizations needed to achieve a given level of coverage for historical and emergent strains, as detailed in the main text.

References

Abbott, R.K., and Crotty, S. (2020). Factors in B cell competition and immunodominance. *Immunological reviews* 296, 120-131. [10.1111/imr.12861](https://doi.org/10.1111/imr.12861).

Abbott, R.K., Lee, J.H., Menis, S., Skog, P., Rossi, M., Ota, T., Kulp, D.W., Bhullar, D., Kalyuzhniy, O., Havenar-Daughton, C., et al. (2018). Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens. *Immunity* 48, 133-146 e136. [10.1016/j.immuni.2017.11.023](https://doi.org/10.1016/j.immuni.2017.11.023).

Akkaya, M., Kwak, K., and Pierce, S.K. (2020). B cell memory: building two walls of protection against pathogens. *Nature reviews. Immunology* 20, 229-238. [10.1038/s41577-019-0244-2](https://doi.org/10.1038/s41577-019-0244-2).

Altman, M.O., Angeletti, D., and Yewdell, J.W. (2018). Antibody Immunodominance: The Key to Understanding Influenza Virus Antigenic Drift. *Viral Immunol* 31, 142-149. [10.1089/vim.2017.0129](https://doi.org/10.1089/vim.2017.0129).

Amitai, A., Sangesland, M., Barnes, R.M., Rohrer, D., Lonberg, N., Lingwood, D., and Chakraborty, A.K. (2020). Defining and Manipulating B Cell Immunodominance Hierarchies to

Elicit Broadly Neutralizing Antibody Responses against Influenza Virus. *Cell Systems* *11*, 573-588.e579. 10.1016/j.cels.2020.09.005.

Andrews, S.F., Cominsky, L.Y., Shimberg, G.D., Gillespie, R.A., Gorman, J., Raab, J.E., Brand, J., Creanga, A., Gajjala, S.R., Narpala, S., et al. (2023). An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans. *Science translational medicine* *15*, eade4976. 10.1126/scitranslmed.ade4976.

Angeletti, D., Gibbs, J.S., Angel, M., Kosik, I., Hickman, H.D., Frank, G.M., Das, S.R., Wheatley, A.K., Prabhakaran, M., Leggat, D.J., et al. (2017). Defining B cell immunodominance to viruses. *Nature immunology* *18*, 456-463. 10.1038/ni.3680.

Angeletti, D., Kosik, I., Santos, J.J.S., Yewdell, W.T., Boudreau, C.M., Mallajosyula, V.V.A., Mankowski, M.C., Chambers, M., Prabhakaran, M., Hickman, H.D., et al. (2019). Outflanking immunodominance to target subdominant broadly neutralizing epitopes. *Proceedings of the National Academy of Sciences of the United States of America* *116*, 13474-13479. 10.1073/pnas.1816300116.

Angeletti, D., and Yewdell, J.W. (2018). Understanding and Manipulating Viral Immunity: Antibody Immunodominance Enters Center Stage. *Trends in immunology* *39*, 549-561. 10.1016/j.it.2018.04.008.

Aung, A., Cui, A., Maiorino, L., Amini, A.P., Gregory, J.R., Bukenya, M., Zhang, Y., Lee, H., Cottrell, C.A., Morgan, D.M., et al. (2023). Low protease activity in B cell follicles promotes retention of intact antigens after immunization. *Science* *379*, eabn8934. 10.1126/science.abn8934.

Batista, F.D., and Neuberger, M.S. (1998). Affinity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate. *Immunity* *8*, 751-759. 10.1016/s1074-7613(00)80580-4.

Bedi, R., Bayless, N.L., and Glanville, J. (2023). Challenges and Progress in Designing Broad-Spectrum Vaccines Against Rapidly Mutating Viruses. *Annu Rev Biomed Data Sci.* 10.1146/annurev-biodatasci-020722-041304.

Bergstrom, J.J., Xu, H., and Heyman, B. (2017). Epitope-Specific Suppression of IgG Responses by Passively Administered Specific IgG: Evidence of Epitope Masking. *Frontiers in immunology* *8*, 238. 10.3389/fimmu.2017.00238.

Boudreau, C.M., and Alter, G. (2019). Extra-Neutralizing FcR-Mediated Antibody Functions for a Universal Influenza Vaccine. *Frontiers in immunology* *10*, 440. 10.3389/fimmu.2019.00440.

Boudreau, C.M., Burke, J.S.t., Roederer, A.L., Gorman, M.J., Mundle, S., Lingwood, D., Delagrave, S., Sridhar, S., Ross, T.M., Kleanthous, H., and Alter, G. (2023). Pre-existing Fc profiles shape the evolution of neutralizing antibody breadth following influenza vaccination. *Cell Rep Med* *4*, 100975. 10.1016/j.xcrm.2023.100975.

Boyoglu-Barnum, S., Ellis, D., Gillespie, R.A., Hutchinson, G.B., Park, Y.J., Moin, S.M., Acton, O.J., Ravichandran, R., Murphy, M., Pettie, D., et al. (2021). Quadrivalent influenza nanoparticle vaccines induce broad protection. *Nature* 592, 623-628. 10.1038/s41586-021-03365-x.

Caradonna, T.M., Ronsard, L., Yousif, A.S., Windsor, I.W., Hecht, R., Bracamonte-Moreno, T., Roffler, A.A., Maron, M.J., Maurer, D.P., Feldman, J., et al. (2022). An epitope-enriched immunogen expands responses to a conserved viral site. *Cell Reports* 41, 111628. 10.1016/j.celrep.2022.111628.

Caradonna, T.M., and Schmidt, A.G. (2021). Protein engineering strategies for rational immunogen design. *NPJ Vaccines* 6, 154. 10.1038/s41541-021-00417-1.

Cheung, C.S., Fruehwirth, A., Pappadimitis, P.C.G., Shen, C.H., Foglierini, M., Joyce, M.G., Leung, K., Piccoli, L., Rawi, R., Silacci-Fregni, C., et al. (2020). Identification and Structure of a Multidonor Class of Head-Directed Influenza-Neutralizing Antibodies Reveal the Mechanism for Its Recurrent Elicitation. *Cell Reports* 32, 108088. 10.1016/j.celrep.2020.108088.

Collins, A.M., and Jackson, K.J.L. (2018). On being the right size: antibody repertoire formation in the mouse and human. *Immunogenetics* 70, 143-158. 10.1007/s00251-017-1049-8.

Comber, L., E, O.M., Jordan, K., Hawkshaw, S., Marshall, L., O'Neill, M., Teljeur, C., Ryan, M., Carnahan, A., Perez Martin, J.J., et al. (2023). Systematic review of the efficacy, effectiveness and safety of high-dose seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥ 18 years of age. *Reviews in Medical Virology* 33, e2330. 10.1002/rmv.2330.

Cox, R.J. (2013). Correlates of protection to influenza virus, where do we go from here? *Human vaccines & immunotherapeutics* 9, 405-408. 10.4161/hv.22908.

Crotty, S. (2015). A brief history of T cell help to B cells. *Nature reviews. Immunology* 15, 185-189. 10.1038/nri3803.

de Carvalho, R.V.H., Ersching, J., Barbulescu, A., Hobbs, A., Castro, T.B.R., Mesin, L., Jacobsen, J.T., Phillips, B.K., Hoffmann, H.H., Parsa, R., et al. (2023). Clonal replacement sustains long-lived germinal centers primed by respiratory viruses. *Cell* 186, 131-146 e113. 10.1016/j.cell.2022.11.031.

De Silva, N.S., and Klein, U. (2015). Dynamics of B cells in germinal centres. *Nature reviews. Immunology* 15, 137-148. 10.1038/nri3804.

Demirden, S.F., Alptekin, K., Kimiz-Gebologlu, I., and Oncel, S.S. (2022). Influenza Vaccine: An Engineering Vision from Virological Importance to Production. *Biotechnology and Bioprocess Engineering* 27, 714-738. 10.1007/s12257-022-0115-8.

DiLillo, D.J., Palese, P., Wilson, P.C., and Ravetch, J.V. (2016). Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. *The Journal of clinical investigation* *126*, 605-610. 10.1172/JCI84428.

Dosenovic, P., Kara, E.E., Pettersson, A.K., McGuire, A.T., Gray, M., Hartweiger, H., Thientosapol, E.S., Stamatatos, L., and Nussenzweig, M.C. (2018). Anti-HIV-1 B cell responses are dependent on B cell precursor frequency and antigen-binding affinity. *Proceedings of the National Academy of Sciences of the United States of America* *115*, 4743-4748. 10.1073/pnas.1803457115.

Feldman, J., Bals, J., Altomare, C.G., St Denis, K., Lam, E.C., Hauser, B.M., Ronsard, L., Sangesland, M., Bracamonte Moreno, T., Okonkwo, V., et al. (2021). Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses. *Science Immunology*, eab15842. 10.1126/sciimmunol.ab15842.

Fiore, A.E., Bridges, C.B., and Cox, N.J. (2009). Seasonal influenza vaccines. *Current topics in microbiology and immunology* *333*, 43-82. 10.1007/978-3-540-92165-3_3.

Fleire, S.J., Goldman, J.P., Carrasco, Y.R., Weber, M., Bray, D., and Batista, F.D. (2006). B cell ligand discrimination through a spreading and contraction response. *Science* *312*, 738-741. 10.1126/science.1123940.

Foote, J., and Eisen, H.N. (1995). Kinetic and affinity limits on antibodies produced during immune responses. *Proceedings of the National Academy of Sciences of the United States of America* *92*, 1254-1256. 10.1073/pnas.92.5.1254.

Foote, J., and Eisen, H.N. (2000). Breaking the affinity ceiling for antibodies and T cell receptors. *Proceedings of the National Academy of Sciences of the United States of America* *97*, 10679-10681. 10.1073/pnas.97.20.10679.

Garcia-Beltran, W.F., St Denis, K.J., Hoelzemer, A., Lam, E.C., Nitido, A.D., Sheehan, M.L., Berrios, C., Ofoman, O., Chang, C.C., Hauser, B.M., et al. (2022). mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. *Cell*. 10.1016/j.cell.2021.12.033.

Garten, R.J., Davis, C.T., Russell, C.A., Shu, B., Lindstrom, S., Balish, A., Sessions, W.M., Xu, X., Skepner, E., Deyde, V., et al. (2009). Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. *Science* *325*, 197-201. 10.1126/science.1176225.

Gaydos, J.C., Top, F.H., Jr., Hodder, R.A., and Russell, P.K. (2006). Swine influenza a outbreak, Fort Dix, New Jersey, 1976. *Emerging infectious diseases* *12*, 23-28. 10.3201/eid1201.050965.

Glanville, J., Zhai, W., Berka, J., Telman, D., Huerta, G., Mehta, G.R., Ni, I., Mei, L., Sundar, P.D., Day, G.M., et al. (2009). Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire. *Proceedings of the National*

Academy of Sciences of the United States of America *106*, 20216-20221. 10.1073/pnas.0909775106.

Goel, R.R., Painter, M.M., Apostolidis, S.A., Mathew, D., Meng, W., Rosenfeld, A.M., Lundgreen, K.A., Reynaldi, A., Khoury, D.S., Pattekar, A., et al. (2021). mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. *Science* *374*, abm0829. 10.1126/science.abm0829.

Hagglof, T., Cipolla, M., Loewe, M., Chen, S.T., Mesin, L., Hartweger, H., ElTanbouly, M.A., Cho, A., Gazumyan, A., Ramos, V., et al. (2023). Continuous germinal center invasion contributes to the diversity of the immune response. *Cell* *186*, 147-161 e115. 10.1016/j.cell.2022.11.032.

Henry, C., Palm, A.E., Krammer, F., and Wilson, P.C. (2018). From Original Antigenic Sin to the Universal Influenza Virus Vaccine. *Trends in immunology* *39*, 70-79. 10.1016/j.it.2017.08.003.

Hong, M., Lee, P.S., Hoffman, R.M., Zhu, X., Krause, J.C., Laursen, N.S., Yoon, S.I., Song, L., Tussey, L., Crowe, J.E., Jr., et al. (2013). Antibody recognition of the pandemic H1N1 Influenza virus hemagglutinin receptor binding site. *Journal of virology* *87*, 12471-12480. 10.1128/JVI.01388-13.

Jordan, K., Murchu, E.O., Comber, L., Hawkshaw, S., Marshall, L., O'Neill, M., Teljeur, C., Harrington, P., Carnahan, A., Perez-Martin, J.J., et al. (2023). Systematic review of the efficacy, effectiveness and safety of cell-based seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥ 18 years of age. *Reviews in Medical Virology* *33*, e2332. 10.1002/rmv.2332.

Kim, Y.M., Pan, J.Y., Korbil, G.A., Peperzak, V., Boes, M., and Ploegh, H.L. (2006). Monovalent ligation of the B cell receptor induces receptor activation but fails to promote antigen presentation. *Proceedings of the National Academy of Sciences of the United States of America* *103*, 3327-3332. 10.1073/pnas.0511315103.

Krammer, F., Garcia-Sastre, A., and Palese, P. (2018). Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Potential Target Antigens and Critical Aspects for a Universal Influenza Vaccine. *Cold Spring Harb Perspect Biol* *10*. 10.1101/cshperspect.a028845.

Krammer, F., and Palese, P. (2013). Influenza virus hemagglutinin stalk-based antibodies and vaccines. *Current opinion in virology* *3*, 521-530. 10.1016/j.coviro.2013.07.007.

Krammer, F., Weir, J.P., Engelhardt, O., Katz, J.M., and Cox, R.J. (2020). Meeting report and review: Immunological assays and correlates of protection for next-generation influenza vaccines. *Influenza and other respiratory viruses* *14*, 237-243. 10.1111/irv.12706.

Kumar, M.D., and Gromiha, M.M. (2006). PINT: Protein-protein Interactions Thermodynamic Database. *Nucleic acids research* *34*, D195-198. 10.1093/nar/gkj017.

- Kuraoka, M., Schmidt, A.G., Nojima, T., Feng, F., Watanabe, A., Kitamura, D., Harrison, S.C., Kepler, T.B., and Kelsoe, G. (2016). Complex Antigens Drive Permissive Clonal Selection in Germinal Centers. *Immunity* 44, 542-552. 10.1016/j.immuni.2016.02.010.
- Lee, J.H., Hu, J.K., Georgeson, E., Nakao, C., Groschel, B., Dileepan, T., Jenkins, M.K., Seumois, G., Vijayanand, P., Schief, W.R., and Crotty, S. (2021). Modulating the quantity of HIV Env-specific CD4 T cell help promotes rare B cell responses in germinal centers. *The Journal of experimental medicine* 218. e20201254. 10.1084/jem.20201254.
- Li, Z., Woo, C.J., Iglesias-Ussel, M.D., Ronai, D., and Scharff, M.D. (2004). The generation of antibody diversity through somatic hypermutation and class switch recombination. *Genes and Development* 18, 1-11. 10.1101/gad.1161904.
- Mahanty, S., Prigent, A., and Garraud, O. (2015). Immunogenicity of infectious pathogens and vaccine antigens. *BMC immunology* 16, 31. 10.1186/s12865-015-0095-y.
- Martin, J.T., Hartwell, B.L., Kumarapperuma, S.C., Melo, M.B., Carnathan, D.G., Cossette, B.J., Adams, J., Gong, S., Zhang, W., Tokatlian, T., et al. (2021). Combined PET and whole-tissue imaging of lymphatic-targeting vaccines in non-human primates. *Biomaterials* 275, 120868. 10.1016/j.biomaterials.2021.120868.
- Mena, I., Nelson, M.I., Quezada-Monroy, F., Dutta, J., Cortes-Fernandez, R., Lara-Puente, J.H., Castro-Peralta, F., Cunha, L.F., Trovao, N.S., Lozano-Dubernard, B., et al. (2016). Origins of the 2009 H1N1 influenza pandemic in swine in Mexico. *Elife* 5. 10.7554/eLife.16777.
- Mesin, L., Ersching, J., and Victora, G.D. (2016). Germinal Center B Cell Dynamics. *Immunity* 45, 471-482. 10.1016/j.immuni.2016.09.001.
- Mesin, L., Schiepers, A., Ersching, J., Barbulescu, A., Cavazzoni, C.B., Angelini, A., Okada, T., Kurosaki, T., and Victora, G.D. (2020). Restricted Clonality and Limited Germinal Center Reentry Characterize Memory B Cell Reactivation by Boosting. *Cell* 180, 92-106 e111. 10.1016/j.cell.2019.11.032.
- Moran, I., Grootveld, A.K., Nguyen, A., and Phan, T.G. (2019). Subcapsular Sinus Macrophages: The Seat of Innate and Adaptive Memory in Murine Lymph Nodes. *Trends in immunology* 40, 35-48. 10.1016/j.it.2018.11.004.
- Moran, I., Nguyen, A., Khoo, W.H., Butt, D., Bourne, K., Young, C., Hermes, J.R., Biro, M., Gracie, G., Ma, C.S., et al. (2018). Memory B cells are reactivated in subcapsular proliferative foci of lymph nodes. *Nature communications* 9, 3372. 10.1038/s41467-018-05772-7.
- Muecksch, F., Wang, Z., Cho, A., Gaebler, C., Ben Tanfous, T., DaSilva, J., Bednarski, E., Ramos, V., Zong, S., Johnson, B., et al. (2022). Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. *Nature* 607, 128-134. 10.1038/s41586-022-04778.

Nachbagauer, R., Feser, J., Naficy, A., Bernstein, D.I., Guptill, J., Walter, E.B., Berlanda-Scorza, F., Stadlbauer, D., Wilson, P.C., Aydillo, T., et al. (2021). A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. *Nature medicine* 27, 106-114. 10.1038/s41591-020-1118-7.

Nachbagauer, R., and Palese, P. (2018). Development of next generation hemagglutinin-based broadly protective influenza virus vaccines. *Current opinion in immunology* 53, 51-57. 10.1016/j.coi.2018.04.001.

Nowak, J., Baker, T., Georges, G., Kelm, S., Klostermann, S., Shi, J., Sridharan, S., and Deane, C.M. (2016). Length-independent structural similarities enrich the antibody CDR canonical class model. *MAbs* 8, 751–760. 10.1080/19420862.2016.1158370.

Nunez, I.A., Carlock, M.A., Allen, J.D., Owino, S.O., Moehling, K.K., Nowalk, P., Susick, M., Diagle, K., Sweeney, K., Mundle, S., et al. (2017). Impact of age and pre-existing influenza immune responses in humans receiving split inactivated influenza vaccine on the induction of the breadth of antibodies to influenza A strains. *PloS one* 12, e0185666. 10.1371/journal.pone.0185666.

Palm, A.E., and Henry, C. (2019). Remembrance of Things Past: Long-Term B Cell Memory After Infection and Vaccination. *Frontiers in immunology* 10, 1787. 10.3389/fimmu.2019.01787.

Pedersen, J.C. (2014). Hemagglutination-inhibition assay for influenza virus subtype identification and the detection and quantitation of serum antibodies to influenza virus. *Methods Mol Biol* 1161, 11-25. 10.1007/978-1-4939-0758-8_2.

Radmacher, M.D., Kelsoe, G., and Kepler, T.B. (1998). Predicted and inferred waiting times for key mutations in the germinal centre reaction: evidence for stochasticity in selection. *Immunology and cell biology* 76, 373-381. 10.1046/j.1440-1711.1998.00753.

Reed, C., Meltzer, M.I., Finelli, L., and Fiore, A. (2012). Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. *Vaccine* 30, 1993-1998. 10.1016/j.vaccine.2011.12.098.

Reusch, L., and Angeletti, D. (2023). Memory B-cell diversity: From early generation to tissue residency and reactivation. *European journal of immunology* 53, e2250085. 10.1002/eji.202250085.

Rockberg, J., and Uhlen, M. (2009). Prediction of antibody response using recombinant human protein fragments as antigen. *Protein science : a publication of the Protein Society* 18, 2346-2355. 10.1002/pro.245.

Ronsard L., Nait Mohamed F.A., Feldman J., Okonkwo V., McCarthy C., Schnabel J., Caradonna T., Barnes R.M., Rohrer D., Lonberg N., Schmidt A.G., and Lingwood D (2023).

Engaging an HIV vaccine target through the acquisition of low B cell affinity. *Nature Communications* 14, 5249. 10.1038/s41467-023-40918-2.

Sabouri, Z., Schofield, P., Horikawa, K., Spierings, E., Kipling, D., Randall, K.L., Langley, D., Roome, B., Vazquez-Lombardi, R., Rouet, R., et al. (2014). Redemption of autoantibodies on anergic B cells by variable-region glycosylation and mutation away from self-reactivity. *Proceedings of the National Academy of Sciences of the United States of America* 111, E2567-2575. 10.1073/pnas.1406974111.

Sandor, A.M., Sturdivant, M.S., and Ting, J.P.Y. (2021). Influenza Virus and SARS-CoV-2 Vaccines. *Journal of immunology* 206, 2509-2520. 10.4049/jimmunol.2001287.

Sangesland, M., Kazer, S.W., Ronsard, L., Bals, J., Boyoglu-Barnum, S., Yousif, A.S., Barnes R., Feldman J., Quirindongo-Crespo, M., McTamney, P.M., Rohrer, D., Lonberg, N., Chackerian B., Graham, B.S., Kanekiyo, M., Shalek, A.K., Lingwood, D. (2019). Germline-encoded affinity for cognate antigen enables vaccine amplification of a human broadly neutralizing response against influenza virus. *Immunity* 51, 1-15 e738. 10.1016/j.immuni.2019.09.001.

Sangesland, M., and Lingwood, D. (2021). Antibody Focusing to Conserved Sites of Vulnerability: The Immunological Pathways for 'Universal' Influenza Vaccines. *Vaccines (Basel)* 9. 10.3390/vaccines9020125.

Sangesland, M., Torrents de la Pena, A., Boyoglu-Barnum, S., Ronsard, L., Mohamed, F.A.N., Moreno, T.B., Barnes, R.M., Rohrer, D., Lonberg, N., Ghebremichael, M., et al. (2022). Allelic polymorphism controls autoreactivity and vaccine elicitation of human broadly neutralizing antibodies against influenza virus. *Immunity* 55, 1693-1709.e1698. 10.1016/j.immuni.2022.07.006.

Schaefer-Babajew, D., Wang, Z., Muecksch, F., Cho, A., Loewe, M., Cipolla, M., Raspe, R., Johnson, B., Canis, M., DaSilva, J., et al. (2023). Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination. *Nature* 613, 735-742. 10.1038/s41586-022-05609.

Schmidt, A.G., Therkelsen, M.D., Stewart, S., Kepler, T.B., Liao, H.X., Moody, M.A., Haynes, B.F., and Harrison, S.C. (2015). Viral receptor-binding site antibodies with diverse germline origins. *Cell* 161, 1026-1034. 10.1016/j.cell.2015.04.028.

Schmidt, F., Muecksch, F., Weisblum, Y., Da Silva, J., Bednarski, E., Cho, A., Wang, Z., Gaebler, C., Caskey, M., Nussenzweig, M.C., et al. (2022). Plasma Neutralization of the SARS-CoV-2 Omicron Variant. *The New England journal of medicine* 386, 599-601. 10.1056/NEJMc2119641.

Schwickert, T.A., Victora, G.D., Fooksman, D.R., Kamphorst, A.O., Mugnier, M.R., Gitlin, A.D., Dustin, M.L., and Nussenzweig, M.C. (2011). A dynamic T cell-limited checkpoint regulates affinity-dependent B cell entry into the germinal center. *The Journal of experimental medicine* 208, 1243-1252. 10.1084/jem.20102477.

Sela-Culang, I., Kunik, V., and Ofran, Y. (2013). The structural basis of antibody-antigen recognition. *Frontiers in immunology* 4, 302. 10.3389/fimmu.2013.00302.

Sencer, D.J. (2011). Perspective: Swine-origin influenza: 1976 and 2009. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 52 *Suppl 1*, S4-7. 10.1093/cid/ciq006.

Silver, J., Zuo, T., Chaudhary, N., Kumari, R., Tong, P., Giguere, S., Granato, A., Donthula, R., Devereaux, C., and Wesemann, D.R. (2018). Stochasticity enables BCR-independent germinal center initiation and antibody affinity maturation. *The Journal of experimental medicine* 215, 77-90. 10.1084/jem.20171022.

Smith, G.J., Vijaykrishna, D., Bahl, J., Lycett, S.J., Worobey, M., Pybus, O.G., Ma, S.K., Cheung, C.L., Raghwani, J., Bhatt, S., et al. (2009). Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. *Nature* 459, 1122-1125. 10.1038/nature08182.

Soema, P.C., Kompier, R., Amorij, J.P., and Kersten, G.F. (2015). Current and next generation influenza vaccines: Formulation and production strategies. *Eur J Pharm Biopharm* 94, 251-263. 10.1016/j.ejpb.2015.05.023.

Spackman, E., and Sitaras, I. (2020). Hemagglutination Inhibition Assay. *Methods Mol Biol* 2123, 11-28. 10.1007/978-1-0716-0346-8_2.

Tam, H.H., Melo, M.B., Kang, M., Pelet, J.M., Ruda, V.M., Foley, M.H., Hu, J.K., Kumari, S., Crampton, J., Baldeon, A.D., et al. (2016). Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination. *Proceedings of the National Academy of Sciences of the United States of America* 113, E6639-E6648. 10.1073/pnas.1606050113.

Tas, J.M., Mesin, L., Pasqual, G., Targ, S., Jacobsen, J.T., Mano, Y.M., Chen, C.S., Weill, J.C., Reynaud, C.A., Browne, E.P., et al. (2016). Visualizing antibody affinity maturation in germinal centers. *Science* 351, 1048-1054. 10.1126/science.aad3439.

Tas, J.M.J., Koo, J.H., Lin, Y.C., Xie, Z., Steichen, J.M., Jackson, A.M., Hauser, B.M., Wang, X., Cottrell, C.A., Torres, J.L., et al. (2022). Antibodies from primary humoral responses modulate the recruitment of naive B cells during secondary responses. *Immunity* 55, 1856-1871. 10.1016/j.immuni.2022.07.020.

Turner, J.S., Zhou, J.Q., Han, J., Schmitz, A.J., Rizk, A.A., Alsoussi, W.B., Lei, T., Amor, M., McIntire, K.M., Meade, P., et al. (2020). Human germinal centres engage memory and naive B cells after influenza vaccination. *Nature* 586, 127-132. 10.1038/s41586-020-2711-0.

Van Beek, M., Nussenzweig, M.C., and Chakraborty, A.K. (2022). Two complementary features of humoral immune memory confer protection against the same or variant antigens. *Proceedings of the National Academy of Sciences of the United States of America* 119, e2205598119. 10.1073/pnas.2205598119.

Van Regenmortel, M.H. (2002). Reductionism and the search for structure-function relationships in antibody molecules. *Journal of molecular recognition : JMR* *15*, 240-247. 10.1002/jmr.584.

Van Regenmortel, M.H. (2011). Limitations to the structure-based design of HIV-1 vaccine immunogens. *Journal of molecular recognition : JMR* *24*, 741-753. 10.1002/jmr.1116.

Victoria, G.D., and Nussenzweig, M.C. (2012). Germinal centers. *Annual review of immunology* *30*, 429-457. 10.1146/annurev-immunol-020711-075032.

Victoria, G.D., and Nussenzweig, M.C. (2022). Germinal Centers. *Annual review of immunology* *40*, 413-442. 10.1146/annurev-immunol-120419-022408.

Wang, S., Mata-Fink, J., Kriegsman, B., Hanson, M., Irvine, D.J., Eisen, H.N., Burton, D.R., Wittrup, K.D., Kardar, M., and Chakraborty, A.K. (2015). Manipulating the selection forces during affinity maturation to generate cross-reactive HIV antibodies. *Cell* *160*, 785-797. 10.1016/j.cell.2015.01.027.

Wei, C.J., Crank, M.C., Shiver, J., Graham, B.S., Mascola, J.R., and Nabel, G.J. (2020). Next-generation influenza vaccines: opportunities and challenges. *Nature Reviews Drug Discovery* *19*, 239-252. 10.1038/s41573-019-0056.

Widge, A.T., Hofstetter, A.R., Houser, K.V., Awan, S.F., Chen, G.L., Burgos Florez, M.C., Berkowitz, N.M., Mendoza, F., Hendel, C.S., Holman, L.A., et al. (2023). An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults. *Science translational medicine* *15*, eade4790. 10.1126/scitranslmed.ade4790.

Xu, R., Ekiert, D.C., Krause, J.C., Hai, R., Crowe, J.E., Jr., and Wilson, I.A. (2010). Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. *Science* *328*, 357-360. 10.1126/science.1186430.

Yang, L., Van Beek, M., Wang, Z., Muecksch, F., Canis, M., Hatziioannou, T., Bieniasz, P.D., Nussenzweig, M.C., and Chakraborty, A.K. (2023). Antigen presentation dynamics shape the antibody response to variants like SARS-CoV-2 Omicron after multiple vaccinations with the original strain. *Cell Reports* *42*, 112256. 10.1016/j.celrep.2023.112256.

Yassine, H.M., Boyington, J.C., McTamney, P.M., Wei, C.J., Kanekiyo, M., Kong, W.P., Gallagher, J.R., Wang, L., Zhang, Y., Joyce, M.G., et al. (2015). Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. *Nature medicine* *21*, 1065-1070. 10.1038/nm.3927.

Young, C., and Brink, R. (2021). The unique biology of germinal center B cells. *Immunity* *54*, 1652-1664. 10.1016/j.immuni.2021.07.015.

Zarnitsyna, V.I., Lavine, J., Ellebedy, A., Ahmed, R., and Antia, R. (2016). Multi-epitope Models Explain How Pre-existing Antibodies Affect the Generation of Broadly Protective Responses to Influenza. *PLoS pathogens* *12*, e1005692. 10.1371/journal.ppat.1005692.

Zhang, J., and Shakhnovich, E.I. (2010). Optimality of mutation and selection in germinal centers. *PLoS computational biology* 6, e1000800. 10.1371/journal.pcbi.1000800.

Zimmer, S.M., and Burke, D.S. (2009). Historical perspective--Emergence of influenza A (H1N1) viruses. *The New England journal of medicine* 361, 279-285. 10.1056/NEJMra0904322.

Figure 1. Divergent amino acid relatedness in the ectodomain and receptor binding site (RBS) patch of the pandemic influenza HA. (A) The HA ectodomain, where relatedness is calculated using the formula " $N_{\text{matched}} / N_{\text{total}}$ "; N_{matched} is the number of amino acids that match between the compared sequences and N_{total} is the total number of amino acids in the aligned sequence. (B) Heat map of HA ectodomain relatedness values for influenza A (H3N2, H1N1) and B viruses spanning >100 years (38 HA ectodomain sequences analyzed). (C) The RBS patch was structurally identified by four human bnAbs whose paratopes engage the RBS by mimicking cell surface sialic acid (CH67, CH67, H2526, 641 I-9) (Schmidt *et al.*, 2015). We defined the RBS patch as the viral sialic acid binding residues (black) + the surrounding antibody epitope 'ring', collectively identified by the peripheral contacts made by the four bnAbs. Amino

relatedness within the RBS patch is then calculated using the same formula except that the residues are now restricted to patch. (D) Heat map of HA RBS patch relatedness values for influenza A (H3N2, H1N1) and B viruses spanning >100 years (RBS patch sequences from the same 38 HA sequences as in B)

Figure 2. Sequential immunization with homologous pHA boosts highly unrelated H1N1 strains. (A) Four year influenza vaccine trial (Nunez *et al.*, 2017). We analyzed HAI elicited from 27 subjects that were longitudinally followed and immunized each year with the vaccine strains indicated. Notably these individuals received the same H1N1 component (pandemic A/California/07/2009) in each of the four years. (B) Fold change in HAI titer (pre vs 20 days post- vaccination) elicited each year and graphed as a function of HA ectodomain relatedness between the vaccine strain and the viruses within the HAI panels. Each dot is a single subject at the relatedness value: white dots are fold changes for strains from the virus panel; the colored dots indicate the vaccine-matched viral strain (relatedness = 1.00). (C) Same data as in (B) only now graphed as a function of RBS patch relatedness between the vaccine strain and the viruses within the panels.

Figure 3. Sequential immunization with homologous pHA gradually broadens the response within individuals with no initial immune memory/recall to historical strains. Responders (green) versus non-responders (red) within each year is graphed for each H1N1 strain in the HAI panel. Responders are defined by having non-increasing fold changes of HAI titers (post-vaccination HAI titer / pre-vaccination HAI titer; i.e. fold change >1). Non-responders are defined by having decreasing fold changes of HAI titers (post-vaccination HAI titer / pre-vaccination HAI titer; fold change < 1). Because non-responders (red) do not back-boost against

historical strains in the panel they, by definition, lack imprinted immunity to these viruses that is recalled by pHA. In the regression analyses each white dot denotes the proportion of non-responders for each viral strain. (A) Yearly response for all longitudinally analyzed individuals; at right is a linear regression of the proportion of non-responders against over the four year vaccine data ($P=6e-04$). (B) Data for subjects >50 years in age ($P=6e-04$, linear regression). (C) Data for subjects <38 years in age ($P=0.0164$, linear regression). See also Figure S1 for linear regression of the proportion of responders in each age group.

Figure 4: The influenza HA head is coarse-grained into three epitopes, that are perceived with different germline-endowed B cell affinities. (A) Diagram of epitope differences. In the right panel, the level of conservation of the three epitopes is depicted using different shapes (not very conserved) or similar shapes (relatively conserved) Epitope 1 (dominant epitope on pHA) varies is not conserved between the three variants. Epitope 2 (subdominant epitope) is relatively conserved between strain 1 (vaccine strain) and strain 2, but not between strains 1 and 3. Epitope 3 (another subdominant epitope) is conserved between strains 1 and 3, but not between strains 2 and 3. (B) Germline-endowed affinity distribution of naive B cells. More dominant epitopes have a longer high-affinity tail. Epitope 1 is more dominant than epitope 2 and epitope 2 is more dominant than epitope 3. Here, the fractions of naive B cells p_i targeting epitope i are $p_1 = 0.8, p_2 = 0.15, p_3 = 0.05$.

Figure 5. Antibody broadening via feedback loops within the humoral response. (A) The antibody titers against both the vaccine strain and historical strains (strains 2 and 3) increase over four immunizations. The antibodies are produced by plasma cells from both the GCs and the EGCs. Antibody coverage increases first for strain 2 (after the second immunization) and strain 3

is engaged after the third immunization. In this simulation, the initial fractions of B cells p_i that target epitope i are $p_1 = 0.8, p_2 = 0.15, p_3 = 0.05$. The conservation ρ_{12} of epitope 2 between strains 1 and 2 and the conservation ρ_{13} of epitope 3 between strains 1 and 3 are both equal to 0.95. (B) The expansion of pathogen-specific IgG antibodies from the first immunization significantly increases the antigen concentration on the FDC in the second immunization. This allows lower-affinity B cells that target subdominant epitopes to enter GCs and undergo affinity maturation. The antigen concentration on the FDC slightly increases from the second to the third immunization, allowing more B cells that target the subdominant epitopes to enter GCs and undergo affinity maturation. (C) The distribution of memory cells produced in the GCs during the first three immunizations. Upon subsequent antigen exposure, these memory cells are selected and expanded in EGCs. Thus, they contribute significantly to circulating antibodies and increased titers during subsequent immunizations. The first immunization primarily produces memory cells that target the dominant epitope (epitope 1), along with some memory cells targeting epitope 2. The second and third vaccinations produce an overall greater number of memory cells overall bearing higher affinity for the subdominant epitopes (epitopes 2 and 3) than the first immunization. (D) Strain 3 is engaged less potently when the initial fractions of B cells p_i that target epitope i are $p_1 = 0.8, p_2 = 0.18, p_3 = 0.02$. (E) The titers against strain 2 are lower than titers against strain 3 when the conservation of epitope 2 is decreased. Here the conservation ρ_{12} of epitope 2 between strains 1 and 2 is 0.7 while the conservation ρ_{13} of epitope 3 between strains 1 and 3 is kept at 0.95. Other values of ρ_{12} are explored in Figure S2. The fractions of B cells p_i that target epitope i are the same as those in Figure 5A.

Figure 6. Regulation of antibody broadening through epitope masking. (A) Maximum antibody titers for the historical strains after the second vaccination, with and without epitope

masking. Two cases are considered when there is epitope masking: [1] the epitopes are absolutely distinct; [2] the epitopes can overlap with each other. The second case is shown here, wherein there is 30 % overlap between epitope 1 (dominant) and epitope 2 (subdominant) and between epitope 1 (dominant) and epitope 3 (subdominant). Masking increases the titers against historical strains, even when there is some overlap between the dominant and subdominant epitopes. (B) Maximum antibody titers for the historical strains after the third vaccination, with and without masking. After the third vaccination, titers for Variant 2 with epitope masking are higher when there is epitope overlap than when the epitopes are distinct. (C) Relative number of memory cells produced with epitope masking. Epitopes are considered to be fully distinct. The epitope that is most targeted by the memory cells is also masked the most after the subsequent immunization. The dominant epitope is targeted most by Vax 1 memory cells and is masked the most in the second immunization. The orange subdominant epitope (epitope 2) and green subdominant epitope (epitope 3) are both relatively well targeted by Vax 2 memory cells. However, the subdominant epitopes are also masked during the third immunization, so the subdominant epitopes lose their advantage compared to the dominant epitope in the affinity maturation process after Vax 3. (D) Relative number of memory cells produced with epitope masking and overlap. The epitope that is most targeted by the memory cells is masked the most in the subsequent immunization. The dominant epitope is targeted most by Vax 1 memory cells and is masked the most in the second immunization. The orange subdominant epitope (epitope 2) is targeted most by Vax 2 memory cells, although more memory cells target the dominant epitope than when the epitopes are fully distinct. Due to the masking of epitope 2 in the third immunization, the dominant and green subdominant epitope (epitope 3) are both relatively well targeted by Vax 3 memory cells.


A



2013	2014	2015	2016
H1N1 CA/07/2009 H3N2 TX/50/2012 B MA/2/2012	H1N1 CA/07/2009 H3N2 TX/50/2012 B MA/2/2012	H1N1 CA/07/2009 H3N2 SW/9715293/2013 B PH/3073/2013 B BR/60/2008	H1N1 CA/07/2009 H3N2 HK/4801/2014 B PH/3073/2013 B BR/60/2008

B

Ectodomain relatedness



C

RBS patch relatedness





FIG 2








FIG 3

A



B




FIG 4




FIG 5




FIG 6